Clinical trial
A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy
NCT04998812
Study timeline
Study start (actual)2022-04-13Date precision: day
Registry last updated2026-04-15
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Multiple Sclerosisunresolved
Clinically Isolated Syndromeunresolved
Interventions
OcrelizumabDRUG · verified · RxNorm: ocrelizumab
Sponsors & collaborators
Hoffmann-La Rochelead sponsor
PPD Development, LPcollaborator
Laboratory Corporation of Americacollaborator
Illingworth Research Groupcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04998812 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.